CommercialCoverageHigh impact
Platelet Rich Plasma and Growth Factor Treatments 2.01.24
Excellus BlueCross BlueShield·Orthopedics, Dermatology, Sports Medicine +3 more·Skin (Dermatology)
Effective date
Jan 22, 2026
We identified it
Jun 20, 2026
Summary
Excellus BlueCross BlueShield policy classifies all Platelet-Rich Plasma (PRP) and growth factor treatments as investigational/experimental for ALL indications, meaning these treatments will not be covered regardless of the medical condition being treated.
Action Required
By January 22, 2026: Billing team must update system to flag CPT 0232T as non-covered/investigational for Excellus BlueCross BlueShield. Providers should be notified that all PRP and growth factor treatments are considered experimental and will not be reimbursed. Patient financial responsibility discussions must occur before treatment. Update encounter forms and prior authorization workflows to reflect non-coverage status.